| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.
|
JAMA
|
2010
|
9.26
|
|
2
|
Raltegravir with optimized background therapy for resistant HIV-1 infection.
|
N Engl J Med
|
2008
|
7.33
|
|
3
|
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
|
N Engl J Med
|
2008
|
5.58
|
|
4
|
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
|
Lancet Infect Dis
|
2011
|
3.58
|
|
5
|
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
|
Lancet
|
2006
|
2.85
|
|
6
|
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
|
Clin Infect Dis
|
2010
|
2.14
|
|
7
|
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
|
Lancet Infect Dis
|
2013
|
1.78
|
|
8
|
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
|
AIDS
|
2007
|
1.73
|
|
9
|
Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era.
|
Dis Colon Rectum
|
2009
|
1.45
|
|
10
|
Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.
|
AIDS
|
2002
|
1.25
|
|
11
|
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
|
Antivir Ther
|
2009
|
1.15
|
|
12
|
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
|
Antimicrob Agents Chemother
|
2002
|
1.05
|
|
13
|
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
|
J Acquir Immune Defic Syndr
|
2012
|
1.01
|
|
14
|
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
|
Antimicrob Agents Chemother
|
2004
|
1.00
|
|
15
|
Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.
|
J Antimicrob Chemother
|
2012
|
0.99
|
|
16
|
Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity.
|
J Virol
|
2011
|
0.99
|
|
17
|
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).
|
J Acquir Immune Defic Syndr
|
2005
|
0.95
|
|
18
|
Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.
|
Antivir Ther
|
2012
|
0.92
|
|
19
|
Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
|
Antivir Ther
|
2009
|
0.90
|
|
20
|
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
|
J Antimicrob Chemother
|
2009
|
0.89
|
|
21
|
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
|
Antivir Ther
|
2014
|
0.89
|
|
22
|
Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).
|
Antivir Ther
|
2014
|
0.88
|
|
23
|
Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
|
J Antimicrob Chemother
|
2012
|
0.87
|
|
24
|
NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
|
AIDS Rev
|
2002
|
0.87
|
|
25
|
Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.
|
AIDS
|
2009
|
0.85
|
|
26
|
Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
|
Antivir Ther
|
2004
|
0.84
|
|
27
|
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
|
Antimicrob Agents Chemother
|
2008
|
0.84
|
|
28
|
Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
|
AIDS
|
2010
|
0.84
|
|
29
|
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
|
Clin Infect Dis
|
2008
|
0.83
|
|
30
|
[Progress in the management of pyogenic cerebral abscesses in non-immunocompromised patients].
|
Ann Med Interne (Paris)
|
2003
|
0.83
|
|
31
|
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.
|
Antimicrob Agents Chemother
|
2011
|
0.81
|
|
32
|
Meningitis due to Capnocytophaga canimorsus: contribution of 16S RNA ribosomal sequencing for species identification.
|
Scand J Infect Dis
|
2006
|
0.81
|
|
33
|
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
|
J Antimicrob Chemother
|
2012
|
0.81
|
|
34
|
Spondylitis due to Mycobacterium xenopi in a human immunodeficiency virus type 1-infected patient: case report and review of the literature.
|
J Clin Microbiol
|
2005
|
0.81
|
|
35
|
What is a modest public health impact?
|
Arch Intern Med
|
2012
|
0.79
|
|
36
|
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
|
Patient
|
2015
|
0.79
|
|
37
|
Enfuvirtide: from basic investigations to current clinical use.
|
Expert Opin Pharmacother
|
2010
|
0.79
|
|
38
|
Darunavir: an effective protease inhibitor for HIV-infected patients.
|
Expert Rev Anti Infect Ther
|
2011
|
0.78
|
|
39
|
Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
|
AIDS
|
2011
|
0.78
|
|
40
|
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
|
Antimicrob Agents Chemother
|
2012
|
0.78
|
|
41
|
Acute lung, heart, liver, and pancreatic involvements with hyponatremia and retinochoroiditis in a 33-year-old French Guianan patient.
|
PLoS Negl Trop Dis
|
2012
|
0.78
|
|
42
|
Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.
|
PLoS One
|
2013
|
0.77
|
|
43
|
Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults.
|
Expert Opin Emerg Drugs
|
2006
|
0.77
|
|
44
|
Deleterious pharmacokinetic interaction between bexarotene and efavirenz.
|
AIDS
|
2010
|
0.76
|
|
45
|
Silicone in HIV-1-infected patients: a cause of misdiagnosed granulomatous disease.
|
Int J Infect Dis
|
2010
|
0.75
|
|
46
|
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
|
J Antimicrob Chemother
|
2012
|
0.75
|
|
47
|
Treatment of latent syphilis in HIV-infected patients with 10 d of benzylpenicillin G benethamine: a prospective study in Maputo, Mozambique.
|
Scand J Infect Dis
|
2002
|
0.75
|
|
48
|
Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
|
Antivir Ther
|
2005
|
0.75
|
|
49
|
Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score.
|
J Acquir Immune Defic Syndr
|
2011
|
0.75
|
|
50
|
Upper respiratory tract involvement in the course of diffuse infiltrative lymphocytosis syndrome in HIV-1-infected patients: report of 2 cases.
|
Clin Infect Dis
|
2005
|
0.75
|
|
51
|
Active tuberculosis does not always imply the initiation of highly active antiretroviral therapy in HIV-infected patients.
|
J Acquir Immune Defic Syndr
|
2008
|
0.75
|
|
52
|
[HIV infection and social condition: a disease which remains singular].
|
Rev Prat
|
2014
|
0.75
|
|
53
|
[HIV infection. Screening, broadcast treatment and prevention of infection are now linked ].
|
Rev Prat
|
2014
|
0.75
|
|
54
|
Budget impact of antiretroviral therapy in a French clinic cohort (ANRS-GOTA).
|
AIDS
|
2017
|
0.75
|
|
55
|
Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
|
J Clin Virol
|
2005
|
0.75
|